Gb002, Inc.
Clinical trials sponsored by Gb002, Inc., explained in plain language.
-
Breathing easier: extended trial tests inhaled therapy for serious lung condition
Disease control OngoingThis study continues testing an inhaled medication called seralutinib for people with pulmonary arterial hypertension (PAH), a serious lung condition. It follows patients who completed earlier seralutinib trials to check long-term safety and whether the treatment keeps helping wi…
Phase: PHASE3 • Sponsor: GB002, Inc. • Aim: Disease control
Last updated Apr 04, 2026 05:07 UTC
-
Inhaled hope for scarred lungs: trial tests new therapy
Disease control TerminatedThis study is testing an inhaled medication called seralutinib for people with high blood pressure in the lungs caused by scarring from another lung disease. The main goal is to see if the drug can help people walk farther in six minutes after 24 weeks of treatment. The trial wil…
Phase: PHASE3 • Sponsor: GB002, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC